X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1708) 1708
Newsletter (30) 30
Magazine Article (14) 14
Book Chapter (6) 6
Conference Proceeding (1) 1
Publication (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (1333) 1333
life sciences & biomedicine (1260) 1260
alendronate (903) 903
alendronate - pharmacology (861) 861
humans (856) 856
female (786) 786
animals (769) 769
osteoporosis (616) 616
alendronate - therapeutic use (464) 464
male (461) 461
pharmacology & pharmacy (410) 410
bone density conservation agents - pharmacology (387) 387
bone density - drug effects (384) 384
bisphosphonates (380) 380
rats (368) 368
endocrinology & metabolism (319) 319
middle aged (312) 312
alendronate - administration & dosage (286) 286
aged (285) 285
osteoporosis - drug therapy (254) 254
diphosphonates - pharmacology (249) 249
bone density conservation agents - therapeutic use (244) 244
osteoporosis, postmenopausal - drug therapy (236) 236
mice (219) 219
orthopedics (211) 211
bones (188) 188
bone density (179) 179
rats, sprague-dawley (173) 173
bone and bones - drug effects (172) 172
alendronic acid (169) 169
bisphosphonate (161) 161
alendronate - adverse effects (153) 153
osteoclasts - drug effects (152) 152
bone density conservation agents - administration & dosage (143) 143
analysis (142) 142
ovariectomy (141) 141
diphosphonates - therapeutic use (139) 139
bone remodeling - drug effects (137) 137
drug therapy (137) 137
fractures (137) 137
etidronic acid - analogs & derivatives (133) 133
time factors (131) 131
dose-response relationship, drug (130) 130
medicine & public health (128) 128
abridged index medicus (123) 123
bone mineral density (123) 123
adult (118) 118
alendronate - chemistry (118) 118
disease models, animal (117) 117
research (116) 116
osteogenesis - drug effects (114) 114
risedronate sodium (114) 114
rats, wistar (113) 113
dentistry (110) 110
aged, 80 and over (108) 108
risk factors (106) 106
postmenopausal women (105) 105
cells, cultured (104) 104
treatment outcome (102) 102
medicine, research & experimental (100) 100
physical sciences (100) 100
research & experimental medicine (100) 100
density (99) 99
bone density conservation agents - adverse effects (98) 98
osteoblasts - drug effects (98) 98
bone resorption (96) 96
bone and bones - metabolism (95) 95
etidronic acid - pharmacology (94) 94
alendronate - pharmacokinetics (92) 92
phosphonates (90) 90
aluminum compounds (87) 87
cell biology (87) 87
chemistry (86) 86
rheumatology (86) 86
general & internal medicine (85) 85
medicine, general & internal (82) 82
diphosphonates - administration & dosage (81) 81
dentistry, oral surgery & medicine (80) 80
etidronic acid - therapeutic use (80) 80
health aspects (80) 80
technology (80) 80
diphosphonates (79) 79
risedronate (79) 79
bone resorption - drug therapy (77) 77
cell line (77) 77
administration, oral (76) 76
endocrinology (75) 75
double-blind method (74) 74
fractures, bone - prevention & control (73) 73
femur - drug effects (72) 72
lumbar vertebrae - drug effects (72) 72
apoptosis (69) 69
osteoclasts (69) 69
absorptiometry, photon (67) 67
surgery (67) 67
drug administration schedule (66) 66
rabbits (66) 66
biochemistry & molecular biology (65) 65
care and treatment (65) 65
dosage and administration (65) 65
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1718) 1718
Japanese (25) 25
Portuguese (15) 15
Chinese (11) 11
German (8) 8
Polish (5) 5
Spanish (5) 5
French (4) 4
Italian (4) 4
Turkish (3) 3
Russian (2) 2
Hungarian (1) 1
Norwegian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Osteoporosis international, ISSN 0937-941X, 1/2012, Volume 23, Issue 1, pp. 305 - 315
Strontium ranelate appears to influence more than alendronate distal tibia bone microstructure as assessed by high-resolution peripheral quantitative computed... 
Osteoporosis | Medicine & Public Health | Alendronate | Orthopedics | Gynecology | Rheumatology | Finite elements analysis | Strontium ranelate | HR-pQCT | Microstructure | Endocrinology | HRpQCT | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Bone and Bones - pathology | Thiophenes - therapeutic use | Radius - pathology | Humans | Middle Aged | Osteoporosis, Postmenopausal - pathology | Tomography, X-Ray Computed | Tibia - pathology | Alendronate - therapeutic use | Bone and Bones - drug effects | Bone and Bones - diagnostic imaging | Osteoporosis, Postmenopausal - diagnostic imaging | Radius - drug effects | Organometallic Compounds - therapeutic use | Female | Finite Element Analysis | Lumbar Vertebrae - physiopathology | Double-Blind Method | Tibia - diagnostic imaging | Bone Density Conservation Agents - therapeutic use | Thiophenes - pharmacology | Tibia - drug effects | Osteoporosis, Postmenopausal - drug therapy | Bone Density Conservation Agents - pharmacology | Bone Density - drug effects | Alendronate - pharmacology | Femur Neck - physiopathology | Osteoporosis, Postmenopausal - physiopathology | Aged | Organometallic Compounds - pharmacology | Radius - diagnostic imaging | Structure | Bones | Analysis | Index Medicus | Dual energy X-ray absorptiometry | Radius | Transformation | Bone turnover | Bisphosphonates | Stress | Post-menopause | Strontium | Alendronic acid | Fractures | Computed tomography | Tibia | Risk assessment | Bone mineral density | Bone strength | Age
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 0027-8424, 9/2014, Volume 111, Issue 35, pp. 12847 - 12852
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 0027-8424, 7/2014, Volume 111, Issue 28, pp. 10287 - 10292
Bone is a favorable microenvironment for tumor growth and a frequent destination for metastatic cancer cells. Targeting cancers within the bone marrow remains... 
Nanoparticles | Femur | Emulsions | Antineoplastics | Multiple myeloma | Fluorescence | Bones | Pretreatment | Polymers | Cancer | Alendronate-PLGA-PEG | Targeting nanomedicine | Bisphosphonate | Bone metastasis | Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Neoplasm Transplantation | Polyglycolic Acid - chemical synthesis | Nanoparticles - chemistry | Humans | Polyglycolic Acid - pharmacology | Polyethylene Glycols - chemistry | Boronic Acids - chemistry | Bone Neoplasms - pathology | Alendronate - chemistry | Bone Neoplasms - metabolism | Drug Delivery Systems | Neoplasms, Experimental - pathology | Multiple Myeloma - drug therapy | Heterografts | Antineoplastic Agents - pharmacology | Bone Neoplasms - drug therapy | Lactic Acid - pharmacology | Tumor Microenvironment - drug effects | Bortezomib | Lactic Acid - chemistry | Nanoparticles - ultrastructure | Polyethylene Glycols - pharmacokinetics | Antineoplastic Agents - chemistry | Multiple Myeloma - metabolism | Xenograft Model Antitumor Assays | Pyrazines - chemistry | Multiple Myeloma - pathology | Animals | Mice, Nude | Polyglycolic Acid - chemistry | Cell Line, Tumor | Mice | Mice, Inbred BALB C | Polyethylene Glycols - chemical synthesis | Lactic Acid - chemical synthesis | Neoplasms, Experimental - metabolism | Pyrazines - pharmacology | Neoplasms, Experimental - drug therapy | Boronic Acids - pharmacology | Rodents | Medical treatment | Tumors | Bone marrow | Metastasis | Polyethylene glycol | Index Medicus | bisphosphonate | Biological Sciences | Physical Sciences | bone metastasis | alendronate-PLGA-PEG | targeting nanomedicine
Journal Article
The New England journal of medicine, ISSN 1533-4406, 01/2014, Volume 370, Issue 5, pp. 412 - 420
Journal Article
Journal Article
Journal Article
Biological & pharmaceutical bulletin, ISSN 0918-6158, 2012, Volume 35, Issue 7, pp. 1096 - 1104
Journal Article
The New England journal of medicine, ISSN 1533-4406, 10/2017, Volume 377, Issue 15, pp. 1417 - 1427
Among postmenopausal women with osteoporosis and a high risk of fracture, treatment with the monoclonal antibody romosozumab for 12 months followed by... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Humans | Antibodies, Monoclonal - adverse effects | Fractures, Bone - epidemiology | Antibodies, Monoclonal - therapeutic use | Risk | Bone Remodeling - drug effects | Alendronate - therapeutic use | Incidence | Spinal Fractures - prevention & control | Female | Drug Therapy, Combination | Bone Density Conservation Agents - adverse effects | Double-Blind Method | Antibodies, Monoclonal - pharmacology | Spinal Fractures - epidemiology | Bone Density Conservation Agents - therapeutic use | Osteoporosis, Postmenopausal - drug therapy | Bone Density Conservation Agents - pharmacology | Alendronate - adverse effects | Bone Density - drug effects | Alendronate - pharmacology | Least-Squares Analysis | Aged | Cardiovascular Diseases - chemically induced | Fractures, Bone - prevention & control | Treatment outcome | Care and treatment | Fractures | Growth | Analysis | Monoclonal antibodies | Bones | Research | Jaw | Femur | Vertebrae | Immunoglobulins | Inhibitor drugs | Osteonecrosis | SOST protein | Bisphosphonates | Hip | Post-menopause | Bone resorption | Osteoporosis | Alendronic acid | Bone growth | Bone density | Drug therapy | Osteogenesis | Index Medicus | Abridged Index Medicus | randomized-trial | metaanalysis | disease | postmenopausal women | strength | bone-mineral density | Klinisk medicin | vertebral fractures | sclerosteosis | Clinical Medicine | aorta | risk
Journal Article
Journal of bone and mineral research, ISSN 0884-0431, 08/2010, Volume 25, Issue 8, pp. 1886 - 1894
Journal Article